Healthcare ETFs Offer Stability Amid Market Volatility and Rising Rates

The healthcare sector has long been seen as a safe bet during uncertain economic times. As market swings grow sharper and tech stocks lose steam, investors often turn to funds like the Health Care Select Sector SPDR (XLV) for stability. Once the top-performing sector in the S&P 500, healthcare now sits in sixth place—but its defensive qualities remain strong. XLV tracks all healthcare stocks in the S&P 500, weighted by company size. The fund’s current valuation sits below 18 times trailing earnings, a level some analysts consider undervalued. Technical signals are also improving: while moving averages haven’t surged yet, the PPO indicator has turned positive.

The sector’s resilience comes from steady demand. Medical treatment remains essential regardless of economic downturns, creating a multitrillion-dollar cushion. Within this, pharmaceuticals stand out due to strong patent protections and consistent global drug spending. Artificial intelligence could further boost profits by cutting research costs and speeding up drug development.

Three key areas drive the sector: medical devices, health insurance, and pure pharmaceuticals. Device makers, however, face pressure from higher long-term interest rates, squeezing their profit margins. Insurers, meanwhile, must navigate shifting regulations, corporate benefit policies, and government reimbursement rates. With improving technical trends and a valuation below historical averages, XLV presents an opportunity for cautious investors. The sector’s mix of inelastic demand, patent-backed earnings, and emerging AI advantages continues to offer stability. Yet challenges like regulatory risks and rising interest costs mean performance will depend on how each subsegment adapts.